肌醇对小于28周早产儿1型早产儿视网膜病变的影响:一项随机临床试验
这项多中心随机临床试验纳入638名小于28周胎龄的早产儿,评估肌醇(40 mg/kg,每12小时一次,最长10周)与安慰剂相比对1型早产儿视网膜病变(ROP)或死亡的影响。结果显示肌醇组死亡或1型ROP发生率显著高于安慰剂组(29% vs 21%),全因死亡率也显著增加(18% vs 11%),试验因肌醇组死亡率显著升高而提前终止。
要点
- 常见严重不良事件包括坏死性小肠结肠炎、灌注不良或低血压、脑室内出血等。
核心结论
- 在小于28周胎龄的早产儿中,使用肌醇长达10周并未降低1型ROP或死亡的风险,且肌醇组死亡率显著更高。
- 这些发现不支持在早产儿中使用肌醇,但试验的提前终止限制了对结论的确定性。
研究设计与样本
- 随机临床试验,纳入638名小于28周胎龄的早产儿,来自美国18个新生儿重症监护中心。
- 入组时间为2014年4月17日至2015年9月4日,末次随访日期为2016年2月12日。
- 计划样本量为1760名参与者,以90%把握度检测死亡或1型ROP绝对减少7%。
- 试验因肌醇组死亡率显著更高而提前终止。
主要发现
- 截至末次给药后7天,常见严重不良事件包括坏死性小肠结肠炎(肌醇组6% vs 安慰剂组4%)、灌注不良或低血压(7% vs 4%)、脑室内出血(10% vs 9%)、全身感染(16% vs 11%)和呼吸窘迫(15% vs 13%)。
临床怎么用
- 对于小于28周胎龄的早产儿,不应使用肌醇来预防1型ROP或死亡。
局限性
- 试验因肌醇组死亡率显著升高而提前终止,限制了结论的确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Previous studies of myo-inositol in preterm infants with respiratory distress found reduced severity of retinopathy of prematurity (ROP) and less frequent ROP, death, and intraventricular hemorrhage. However, no large trials have tested its efficacy or safety. OBJECTIVE: To test the adverse events and efficacy of myo-inositol to reduce type 1 ROP among infants younger than 28 weeks' gestational age. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial included 638 infants younger than 28 weeks' gestational age enrolled from 18 neonatal intensive care centers throughout the United States from April 17, 2014, to September 4, 2015; final date of follow-up was February 12, 2016. The planned enrollment of 1760 participants would permit detection of an absolute reduction in death or type 1 ROP of 7% with 90% power. The trial was terminated early due to a statistically significantly higher mortality rate in the myo-inositol group. INTERVENTIONS: A 40-mg/kg dose of myo-inositol was given every 12 hours (initially intravenously, then enterally when feeding; n = 317) or placebo (n = 321) for up to 10 weeks. MAIN OUTCOMES AND MEASURES: Type 1 ROP or death before determination of ROP outcome was designated as unfavorable. The designated favorable outcome was survival without type 1 ROP. RESULTS: Among 638 infants (mean, 26 weeks' gestational age; 50% male), 632 (99%) received the trial drug or placebo and 589 (92%) had a study outcome. Death or type 1 ROP occurred more often in the myo-inositol group vs the placebo group (29% vs 21%, respectively; adjusted risk difference, 7% [95% CI, 0%-13%]; adjusted relative risk, 1.41 [95% CI, 1.08-1.83], P = .01). All-cause death before 55 weeks' postmenstrual age occurred in 18% of the myo-inositol group and in 11% of the placebo group (adjusted risk difference, 6% [95% CI, 0%-11%]; adjusted relative risk, 1.66 [95% CI, 1.14-2.43], P = .007). The most common serious adverse events up to 7 days of receiving the ending dose were necrotizing enterocolitis (6% for myo-inositol vs 4% for placebo), poor perfusion or hypotension (7% vs 4%, respectively), intraventricular hemorrhage (10% vs 9%), systemic infection (16% vs 11%), and respiratory distress (15% vs 13%). CONCLUSIONS AND RELEVANCE: Among premature infants younger than 28 weeks' gestational age, treatment with myo-inositol for up to 10 weeks did not reduce the risk of type 1 ROP or death vs placebo. These findings do not support the use of myo-inositol among premature infants; however, the early termination of the trial limits definitive conclusions.
引用
- Phelps DL, Watterberg KL, Nolen TL, et al. Effects of Myo-inositol on Type 1 Retinopathy of Prematurity Among Preterm Infants <28 Weeks' Gestational Age: A Randomized Clinical Trial. JAMA. 2018. PMID: 30357297. doi:10.1001/jama.2018.14996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。